Acne Vulgaris - Market Insights, Epidemiology and Market Forecast – 2025
This report can be delivered to the clients within 7-10 Business Days
DelveInsight’s “Acne Vulgaris - Market Insights, Epidemiology and Market Forecast – 2025” report provides an overview of the disease and in depth research related to Acne Vulgaris for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025.
This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Acne Vulgaris. It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Acne Vulgaris for 7 major markets.
The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the
Report highlights the frontrunners, the drivers and barriers for the Acne Vulgaris market, as well as treatment algorithm, current treatments & advancements are included.
The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Acne Vulgaris, providing an in-depth analysis of emerging therapies which will create an impact through their launch.
According to DelveInsight, the forecasted patient population of Acne Vulgaris for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Acne Vulgaris 7MM market size is estimated to be USD XX by 2025.The DelveInsight Report will help in enhanced understanding of the Acne Vulgaris market from inside out, with transparency into the calculated patient forecasting data and estimated market size.
KEY COVERAGE
DelveInsight’s “Acne Vulgaris - Market Insights, Epidemiology and Market Forecast – 2025” report provides an overview of the disease and in depth research related to Acne Vulgaris for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025.
This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Acne Vulgaris. It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Acne Vulgaris for 7 major markets.
The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the
Report highlights the frontrunners, the drivers and barriers for the Acne Vulgaris market, as well as treatment algorithm, current treatments & advancements are included.
The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Acne Vulgaris, providing an in-depth analysis of emerging therapies which will create an impact through their launch.
According to DelveInsight, the forecasted patient population of Acne Vulgaris for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Acne Vulgaris 7MM market size is estimated to be USD XX by 2025.The DelveInsight Report will help in enhanced understanding of the Acne Vulgaris market from inside out, with transparency into the calculated patient forecasting data and estimated market size.
KEY COVERAGE
- Understanding historical and forecasted epidemiological data for Acne Vulgaris covering 7MM from 2015-2025.
- Segment level epidemiology and market split for Acne Vulgaris.
- The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Acne Vulgaris.
- The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Acne Vulgaris market trends.
- Thorough market distribution based on market share for Acne Vulgaris.
- The report will help in developing business strategies by understanding trends shaping and driving the Acne Vulgaris market.
- To understand the future market competition in the Acne Vulgaris market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Acne Vulgaris in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
- Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
1. REPORT INTRODUCTION
2. ACNE VULGARIS MARKET OVERVIEW AT A GLANCE
2.1. Total Market Share Distribution of Acne Vulgaris for 7 MM in 2016
2.2. Total Market Share Distribution of Acne Vulgaris for 7 MM in 2025
3. ACNE VULGARIS
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1.1. United States
4.1.1.1. Diagnosed Cases of Acne Vulgaris in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Acne Vulgaris in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Acne Vulgaris in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Acne Vulgaris in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Acne Vulgaris in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Acne Vulgaris in United Kingdom
5. TREATMENT ALGORITHM
5.1.1. Treatment Guidelines/Practices
6. MARKETED DRUGS FOR ACNE VULGARIS
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status
7. EMERGING THERAPIES
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase
8. OVERVIEW OF TOTAL ACNE VULGARIS MARKET (2016 & 2025)
9. ACNE VULGARIS : COUNTRY-WISE MARKET ANALYSIS
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)
10. MARKET DRIVERS
11. MARKET RESTRAINTS
12. APPENDIX
13. REPORT METHODOLOGY
14. CONSULTING SERVICES
15. DISCLAIMER
16. ABOUT DELVEINSIGHT
2. ACNE VULGARIS MARKET OVERVIEW AT A GLANCE
2.1. Total Market Share Distribution of Acne Vulgaris for 7 MM in 2016
2.2. Total Market Share Distribution of Acne Vulgaris for 7 MM in 2025
3. ACNE VULGARIS
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1.1. United States
4.1.1.1. Diagnosed Cases of Acne Vulgaris in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Acne Vulgaris in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Acne Vulgaris in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Acne Vulgaris in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Acne Vulgaris in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Acne Vulgaris in United Kingdom
5. TREATMENT ALGORITHM
5.1.1. Treatment Guidelines/Practices
6. MARKETED DRUGS FOR ACNE VULGARIS
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status
7. EMERGING THERAPIES
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase
8. OVERVIEW OF TOTAL ACNE VULGARIS MARKET (2016 & 2025)
9. ACNE VULGARIS : COUNTRY-WISE MARKET ANALYSIS
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)
10. MARKET DRIVERS
11. MARKET RESTRAINTS
12. APPENDIX
13. REPORT METHODOLOGY
14. CONSULTING SERVICES
15. DISCLAIMER
16. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Diagnosed Cases Acne Vulgaris in United States (2015-2025)
Table 2: Diagnosed Cases Acne Vulgaris in Germany (2015-2025)
Table 3: Diagnosed Cases Acne Vulgaris in France (2015-2025)
Table 4: Diagnosed Cases Acne Vulgaris in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Acne Vulgaris in Spain (2015-2025)
Table 6: Diagnosed Cases Acne Vulgaris in Italy (2015-2025)
Table 7: Diagnosed Cases Acne Vulgaris in Japan (2015-2025)
Table 8: List of Marketed Drugs for Acne Vulgaris
Table 9: List of Pipeline Phase III Drugs for Acne Vulgaris
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Acne Vulgaris in USD, Million (2015-2025)
Table 17: Germany Market Size of Acne Vulgaris in USD, Million (2015-2025)
Table 18: France Market Size of Acne Vulgaris in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Acne Vulgaris in USD, Million (2015-2025)
Table 20: Spain Market Size of Acne Vulgaris in USD, Million (2015-2025)
Table 21: Italy Market Size of Acne Vulgaris in USD, Million (2015-2025)
Table 22: Japan Market Size of Acne Vulgaris in USD, Million (2015-2025)
Table 1: Diagnosed Cases Acne Vulgaris in United States (2015-2025)
Table 2: Diagnosed Cases Acne Vulgaris in Germany (2015-2025)
Table 3: Diagnosed Cases Acne Vulgaris in France (2015-2025)
Table 4: Diagnosed Cases Acne Vulgaris in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Acne Vulgaris in Spain (2015-2025)
Table 6: Diagnosed Cases Acne Vulgaris in Italy (2015-2025)
Table 7: Diagnosed Cases Acne Vulgaris in Japan (2015-2025)
Table 8: List of Marketed Drugs for Acne Vulgaris
Table 9: List of Pipeline Phase III Drugs for Acne Vulgaris
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Acne Vulgaris in USD, Million (2015-2025)
Table 17: Germany Market Size of Acne Vulgaris in USD, Million (2015-2025)
Table 18: France Market Size of Acne Vulgaris in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Acne Vulgaris in USD, Million (2015-2025)
Table 20: Spain Market Size of Acne Vulgaris in USD, Million (2015-2025)
Table 21: Italy Market Size of Acne Vulgaris in USD, Million (2015-2025)
Table 22: Japan Market Size of Acne Vulgaris in USD, Million (2015-2025)
LIST OF FIGURES
Figure 1: Diagnosed Cases Acne Vulgaris in United States (2015-2025)
Figure 2: Diagnosed Cases Acne Vulgaris in Germany (2015-2025)
Figure 3: Diagnosed Cases Acne Vulgaris in France (2015-2025)
Figure 4: Diagnosed Cases Acne Vulgaris in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Acne Vulgaris in Spain (2015-2025)
Figure 6: Diagnosed Cases Acne Vulgaris in Italy (2015-2025)
Figure 7: Diagnosed Cases Acne Vulgaris in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Acne Vulgaris
Figure 9: List of Pipeline Phase III Drugs for Acne Vulgaris
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Acne Vulgaris in USD, Million (2015-2025)
Figure 17: Germany Market Size of Acne Vulgaris in USD, Million (2015-2025)
Figure 18: France Market Size of Acne Vulgaris in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Acne Vulgaris in USD, Million (2015-2025)
Figure 20: Spain Market Size of Acne Vulgaris in USD, Million (2015-2025)
Figure 21: Italy Market Size of Acne Vulgaris in USD, Million (2015-2025)
Figure 22: Japan Market Size of Acne Vulgaris in USD, Million (2015-2025)
Figure 1: Diagnosed Cases Acne Vulgaris in United States (2015-2025)
Figure 2: Diagnosed Cases Acne Vulgaris in Germany (2015-2025)
Figure 3: Diagnosed Cases Acne Vulgaris in France (2015-2025)
Figure 4: Diagnosed Cases Acne Vulgaris in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Acne Vulgaris in Spain (2015-2025)
Figure 6: Diagnosed Cases Acne Vulgaris in Italy (2015-2025)
Figure 7: Diagnosed Cases Acne Vulgaris in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Acne Vulgaris
Figure 9: List of Pipeline Phase III Drugs for Acne Vulgaris
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Acne Vulgaris in USD, Million (2015-2025)
Figure 17: Germany Market Size of Acne Vulgaris in USD, Million (2015-2025)
Figure 18: France Market Size of Acne Vulgaris in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Acne Vulgaris in USD, Million (2015-2025)
Figure 20: Spain Market Size of Acne Vulgaris in USD, Million (2015-2025)
Figure 21: Italy Market Size of Acne Vulgaris in USD, Million (2015-2025)
Figure 22: Japan Market Size of Acne Vulgaris in USD, Million (2015-2025)
